Barry Marshall

Dr. Barry Marshall Shares Xcelerate's Mission In Advancing Medical Technology On ticker NEWS' Globally-Streamed Broadcast

Retrieved on: 
Thursday, May 13, 2021
Crawley, Western Australia, Barry Marshall, Marshall, University of Western Australia, Occupations, Names, Learned societies

FRACP, FAA,FRS,MBBS-UWA, who sits on the Advisory Board of Xcelerate, Inc. shared the Company\'s mission of advancing medical technology in live appearance on Australia\'s ticker NEWS \' globally streamed broadcast.\nIn an in-depth interview, Dr. Marshall spoke about Xcelerate\'s mission of finding innovative acquisitions within the patent/engineering world.

Key Points: 
  • FRACP, FAA,FRS,MBBS-UWA, who sits on the Advisory Board of Xcelerate, Inc. shared the Company\'s mission of advancing medical technology in live appearance on Australia\'s ticker NEWS \' globally streamed broadcast.\nIn an in-depth interview, Dr. Marshall spoke about Xcelerate\'s mission of finding innovative acquisitions within the patent/engineering world.
  • Dr. Marshall spoke about the significant advantages he has realized working with an American listed public company, particularly in the area of funding.
  • and follow them on Twitter @XcelerateUS.\nProfessor Barry Marshall is a Nobel Prize Laureate, Professor of Clinical Microbiology at The University of Western Australia.
  • Today, Professor Marshall is Director of The Marshall Centre for Infectious Diseases Research and Training, which was founded in his honor.

Nobel Prize Laureate Dr. Barry Marshall to Join Advisory Board of Xcelerate, Inc.

Retrieved on: 
Tuesday, February 23, 2021
Medical specialties, Bacteria, Clinical medicine, Infectious causes of cancer, Epsilonproteobacteria, Gram-negative bacteria, Pathogenic bacteria, Barry Marshall, Helicobacter pylori, Peptic ulcer disease, Robin Warren, Peptic

MAULDIN, S.C., Feb. 23, 2021 /PRNewswire/ --Xcelerate, Inc. (OTC: UDHI) is honored to announce Barry James Marshall AC FRACP FRS FAA will join its Advisory Board, effective immediately.

Key Points: 
  • MAULDIN, S.C., Feb. 23, 2021 /PRNewswire/ --Xcelerate, Inc. (OTC: UDHI) is honored to announce Barry James Marshall AC FRACP FRS FAA will join its Advisory Board, effective immediately.
  • In 2005 Dr. Marshall and his longtime collaborator Dr. Robin Warren were awarded the Nobel Prize in Physiology or Medicine for their discovery of the bacterium Helicobacter pylori (H. pylori) and its role in peptic ulcer disease.
  • This discovery also established the causative link between Helicobacter pylori infection and stomach cancer.
  • Currently Dr. Marshall serves as Clinical Professor and Director of The Marshall Centre for Infectious Diseases Research at University of Western Australia.

Crestone, Inc. (Boulder, Colorado) Secures NIH Funding for Preclinical Development of Novel Antibiotic CRS3123 to Treat H. pylori Infections

Retrieved on: 
Monday, April 27, 2020
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Medical specialties, RTT, Medicine, Infectious causes of cancer, Clinical medicine, Helicobacter pylori, Gastritis, Clostridioides difficile, Stomach cancer, Barry Marshall

CRS3123 is also entering a phase 2 clinical study for treatment of Clostridioides difficile infections under a separate NIH contract with Crestone.

Key Points: 
  • CRS3123 is also entering a phase 2 clinical study for treatment of Clostridioides difficile infections under a separate NIH contract with Crestone.
  • H. pylori is a bacterium known to be present in the stomachs of more than half the people in the world.
  • Complications associated with H. pylori infection occur in about 10% of people and include gastritis, ulcers or stomach cancer.
  • The WHO has classified H. pylori as a class I carcinogen and recently listed drug-resistant H. pylori as a priority pathogen.